Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

Certara2026 年 5 月 6 日

Blog

GxP compliance in the cloud: What IT teams need to rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

Certara2026 年 5 月 4 日

Webinar

ICH M13B Strength Biowaiver

Certara2026 年 4 月 28 日

Blog

From models to impact: What QSPC 2026 revealed about the future of drug development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

Certara2026 年 4 月 28 日

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

Blog Knowledge Base

Mean residence time (MRT): Understanding how long drug molecules stay in the body

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 16 日 When I first began learning about pharmacokinetics (PK), I was often…

Ana Henry2026 年 4 月 16 日

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

Certara2026 年 4 月 10 日

Blog

PK parameters explained: From Cmax to clearance (and why it matters for development decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

Sebastian Kuechenmeister2026 年 4 月 9 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – PK/PD

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

GxP compliance in the cloud: What IT teams need to rethink

ICH M13B Strength Biowaiver

From models to impact: What QSPC 2026 revealed about the future of drug development

ADC dose optimization: Applying model-informed strategies in development

Mean residence time (MRT): Understanding how long drug molecules stay in the body

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK parameters explained: From Cmax to clearance (and why it matters for development decisions)

订阅时事通讯

快捷链接

解决方案

联系我们